GALACTIC-HF: Investor/Media Event
Nov 13, 2020 1:00 PM EST
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose employment commenced in November 2020 as
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes
SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in virtual fireside chats at the Piper Sandler 32 nd Annual Healthcare Conference taking
Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF Company to Host Conference Call and Webcast Today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov.
